Figure 1 (IMAGE)

Compuscript Ltd

Figure 1

Caption

Dysregulation of CXCR4/CXCL12 signaling is associated with many inflammatory diseases. EPI-X4 is an endogenous peptide antagonist of CXCR4. Molecular docking and mutational analysis allowed to increase its anti-CXCR4 activity. The optimized EPI-X4 JM#21 derivative prevented inflammatory responses in mouse models of atopic dermatitis and allergen-induced asthma.

Credit

APSB

Usage Restrictions

No restrictions.

License

Public Domain

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.